Adherium's smart inhalers

AstraZeneca to offer Adherium’s smart inhalers to asthma and COPD patients

With Adherium's smartphone-connected device, the medication adherence increases by up to 59% in adults and 180% in children with asthma.
Adherium

Smart inhaler maker Adherium raises $25.6M in an IPO

The New Zealand-based company got $3 million from AstraZeneca with which it recently signed a long-term commercialization agreement.
Smart inhalers

Study: Smart inhaler can boosts medication adherence by 144 percent

Also the three studies Adherium has conducted have found a 14.9% increase in lung function and a 37% reduction in oral steroid usage.
smart inhalers

Adherium smart inhalers to be used in a multi-country study

Researchers plan to recruit 675 adults to investigate the safety and efficacy of three different treatment regimens for mild asthma.
adherium research

Study: Adherium’s Smartinhaler improves clinical outcomes, medication adherence in children with asthma

The study demonstrated a five-fold reduction in asthma-related hospitalizations observed in patients using Adherium's Smartinhaler.